- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What You May Have Missed at Asembia 2023
The 2023 Asembia Specialty Pharmacy Summit took place in early May in Las Vegas, Nevada, and The American Journal of Managed Care® was there to cover the meeting—catch up on what you may have missed.
Here are the top stories from the 2023 Asembia Specialty Pharmacy Summit, which took place April 30 to May 4 in Las Vegas, Nevada.
An Overview of the Specialty Therapy Pipeline in 2023
At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.
Dr Fran Gregory Discusses the Implications of a New Wave of Biosimilars
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a “second wave” of biosimilars hitting the market.
Survey Shows Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product
Speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.
Payers, Drug Manufacturers Can Expect More Liability Under New IRA Drug Pricing Policies
Panelists at Asembia 2023 discussed the myriad of ways that the drug pricing policies of the Inflation Reduction Act (IRA), such as inflation rebates and a redesign of Medicare Part D plans, will affect payers and manufacturers.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
5 Key Drug Approvals and CRLs in 2024
December 27th 2024In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.
Read More
From Approval to Practice: Addressing the Hurdles in Biosimilar Integration
December 12th 2024Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.
Read More
